Optimizing therapy of seizures in patients with renal or hepatic dysfunction

Neurology

Volumn 67, Issue 12 SUPPL. 4, 2006, Pages

  Lacerda, Glenda ^a   Krummel, Thierry ^a   Sabourdy, Cécile ^a   Ryvlin, Philippe ^b   Hirsch, Edouard ^a,c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c Service de Neurologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; METHOTREXATE; OXCARBAZEPINE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ACUTE KIDNEY TUBULE NECROSIS; BRAIN HEMORRHAGE; BRAIN LYMPHOMA; CLINICAL TRIAL; DIALYSIS ENCEPHALOPATHY; DISEASE EXACERBATION; DRUG EXCRETION; DRUG METABOLISM; DRUG USE; ENZYME METABOLISM; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; MYCOSIS; MYOCLONUS; NEPHROLITHIASIS; NEUROTOXICITY; PRIORITY JOURNAL; PYRIDOXINE DEFICIENCY; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; UREMIA; WILSON DISEASE;

EID: 33845709780     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.12_suppl_4.s28     Document Type: Review

References (41)

1. Aminoff MJ, Parent JM. Comorbidity in adults. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven Publishers, 1997;184:1957-1959.
2. Nolin TD, Freye RF, Matzhe GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003;42:906-925.
3. Leblond F, Guévin C, Demers C, et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001;12:326-332.
4. George J, Liddle C, Murray M, Byth K, Farrel GC. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995;49:873-881.
5. Victor M, Ropper A. The acquired metabolic disorders of the nervous system. In: AH Ropper, RJ Brown, eds. Adams and Victor's principles of neurology. 7th ed. New York: McGraw-Hill, 2001:1184-1190.
6. Palmer CA. Neurologic manifestations of renal disease. Neurol Clin 2002;20:23-34.
7. Martínez-Rodríguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001;111:115-119.
8. Tattevin P, Messiaen T, Pras V, Ronco P, Biour M. Confusion and general seizures following ciprofloxacin administration. Nephrol Dial Transplant 1998;13:2712-2713.
9. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:649-687.
10. Krishnan V, Murray P. Pharmacological issues in the critically ill. Clin Chest Med 2003;24:671-688.
11. Sen S, Ratnaraj N, Davies NA, et al. Treatment of phenytoin toxicity by molecular adsorbents recirculating system (MARS). Epilepsia 2003;44:265-267.
12. De Schoenmakere G, De Waele J, Terryn W, et al. Phenytoin intoxication in critically ill patients. Am J Kid Dis 2004;45:189-192.
13. nd ed. New York: Elsevier 2003:1177-1181.
14. Zahiri K, Launay-Vacher V, Deray G. Guide de prescription des médicamens chez le patient insuffisant renal. Paris: Meditions International, 2000.
15. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002;10:986-993.
16. Danlami ZT, Obeid T, Awada A, et al. Absence status: an overlooked cause of acute confusion in hemodialysis patients. J Nephrol 1998;11:146-147.
17. Zhang C, Glenn DG, Bell WL, O'Donovan CA. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia 2005;46:156-158.
18. Bergin AM, Connolly M. New antiepileptic drug therapies. Neurol Clin North Am 2002;20:1163-1182.
19. Knorr M, Schaper J, Harjes M, et al. Fanconi syndrome caused by antiepileptic therapy with valproic acid. Epilepsia 2004;45:868-871.
20. Altunbasak S, Yildizdas D, Anarat A, et al. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol 2001;16:256-259.
21. Ijiri Y, Inoue T, Fukuda F, et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 2004;45:924-927.
22. Alpay H, Altun O, Biyikh NK. Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. Pediatr Nephrol 2004;19:445-447.
23. Ptasalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481.
24. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptics and chemotherapeutic agents. Lancet Neurol 2003;2:404-409.
25. Shet RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63(10 suppl 4):S24-29.
26. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63(10 suppl 4):S24-29.
27. Gopaul S, Farrel K, Abbrot P. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003;44:322-328.
28. French JA, Kanner Am, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs: treatment of refractory epilepsy. Neurology 2004;62:1261-1273.
29. French JA, Kanner Am, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs: treatment of new onset epilepsies. Neurology 2004;62:1252-1260.
30. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3:618-621.
31. Türk-Börü U, Koçer A, Alp R, et al. Status epilepticus in a case of Wilson's disease during D-penicillamine treatment. Swiss Med Wkly 2003;133:446-447.
32. Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc 2003;35:1480-1481.
33. Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Therap 2006;28:734-744.
34. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47:1128-1135.
35. Wong F. Liver and kidney diseases. Clin Liver Dis 2002;6:981-1011.
36. Eleftheriadis N, Fourla E, Eleftheriadis D, Karlovasitou A. Status epilepticus as a manifestation of hepatic encephalopathy. Acta Neurol Scand 2003;107:142-144.
37. Lewis MB, Howdle PD. Neurologic complications of liver transplantation in adults. Neurology 2003;61:1174-1178.
38. Krasko A, Deshpande K, Bonvino S. Liver failure, transplantation and critical care. Crit Care Clin 2003;19:155-183.
39. Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure - a controlled clinical trial. J Hepatol 2004;41:89-96.
40. Gaida-Hommernick B, Rieck K, Runge U. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001;42:793-795.
41. Chemmanur AT, Bonkosky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004;8:807-838.